Abstract: The present disclosure generally relates to methods of and uses for treating Prader-Willi Syndrome (PWS) in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formulas I, II, III or IV, or a pharmaceutically acceptable salt, hydrate, stereoisomer, or prodrug thereof, or for use in the manufacture of a medicament as described herein.
Abstract: The present invention features crystalline forms of Compound I, including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.
Type:
Application
Filed:
October 5, 2023
Publication date:
April 25, 2024
Inventors:
Kaicheng Zhu, Tao Wang, Joseph Helble, Anthony Toto, Jiajun Zhang, George G. Wu, Yat Sun Or
Abstract: Benzazepine derivatives, compositions comprising therapeutically effective amounts of those benzazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders or associated with risk factors for cognitive impairment. In particular, it relates to the use of a ?5-containing GABAA R agonist (e.g.
Type:
Application
Filed:
August 18, 2023
Publication date:
April 25, 2024
Inventors:
Belew Mekonnen, John A. Butera, Jianxing Huang, Hemantbhai Patel
Abstract: The present invention relates to compounds of formula (I), which are modulators of sortilin activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions where modulation of sortilin activity is beneficial.
Type:
Application
Filed:
January 20, 2022
Publication date:
April 25, 2024
Inventors:
Paul Brian LITTLE, Manuel Javier CASES-THOMAS, Mads Fuglsang KJØLBY, Anders NYKJÆR
Abstract: The present invention provides a toxin molecule suitable for an antibody drug conjugate. In particular, the present invention provides a compound represented by formula (I) below or a pharmaceutically acceptable salt or hydrate thereof. The compound of the present invention can be used in the preparation of a pharmaceutical composition for treating diseases associated with tumor cell proliferation.
Abstract: The present application relates to an anti-tumor compound and a preparation method and use thereof, and in particular to a compound or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a preparation method and use thereof.
Abstract: A compound represented by formula (I), or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotope marker, isomer or prodrug thereof. Also provided are a pharmaceutical composition comprising the same, and the use of the compound and the pharmaceutical composition in the preparation of a medicament for treating tyrosine kinase-mediated diseases. The provided compound and the pharmaceutical composition thereof have significant tyrosine kinase inhibitory activity, can overcome tumor drug resistance, can break through the blood-brain barrier, and further have excellent pharmacokinetic properties and excellent oral bioavailability, and can be administered in a small dose, thereby reducing treatment cost for patients and possible side effects; therefore, the provided compound and the pharmaceutical composition thereof have great application potentials.
Abstract: The present disclosure relates to a cephalosporin antibacterial compound and a preparation method therefor. The cephalosporin antibacterial compound can exhibit antibacterial activity against Gram-negative bacteria and other bacteria.
Type:
Application
Filed:
January 12, 2022
Publication date:
April 25, 2024
Inventors:
Jian HUANG, Lingjian ZHU, Yang ZOU, Cili ZHANG
Abstract: Compounds represented by formula (I), compounds of the less-polar group of two groups of diastereomers in which the carbon atom indicated by * in formula (II) is an asymmetric carbon atom, salts of the compounds, and solvates of the compounds or salts. The compounds have Nrf2 activating action.
Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat inflammatory bowel diseases, and processes and intermediates useful for preparing such compounds.
Type:
Application
Filed:
September 5, 2023
Publication date:
April 25, 2024
Inventors:
Ryan Hudson, Jennifer Kozak, Paul R. Fatheree, Dante D. Podesto, Gary E.L. Brandt, Melissa Fleury, Anne-Marie Beausoleil, Xiaojun Huang, Venkat R. Thalladi
Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein R1, R2, A, E1, E2, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
Abstract: The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating PARP1 activity and may be used in the treatment of disorders in which PARP1 activity is implicated, such as cancer.
Type:
Application
Filed:
August 29, 2023
Publication date:
April 25, 2024
Inventors:
Jayakanth KANKANALA, Jeremy D. PETTIGREW, Aurelia CONTE, Jiyun CHEN, Son Minh PHAM
Abstract: This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4?-(((((2,2?-dichloro-[1,1?-biphenyl]-3,3?-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.
Type:
Application
Filed:
November 21, 2023
Publication date:
April 25, 2024
Inventors:
Zhongjiang Jia, Shili Chen, Yi Li, Timothy Martin, Bo Shen, Naijing Su, Jiacheng Zhou, Qun Li
Abstract: The present disclosure describes boron containing pyrimidine compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the present disclosure have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described.
Type:
Application
Filed:
June 16, 2023
Publication date:
April 25, 2024
Inventors:
ALAN LONG, SHON R. PULLEY, KEITH ANDREW NEWTON GRAHAM, CHUNLIANG LIU, YASHEEN ZHOU
Abstract: The present application provides a preparation method for trimethyl aluminum, comprising the steps of: reacting methyl aluminum dichloride or sesquimethyl aluminium chloride or dimethyl aluminum chloride with a system of metal M and methyl chloride in the presence of catalyst and solvent to produce trimethyl aluminum and chloride of metal M; wherein the catalyst is selected from metals or their ions which rank after metallic aluminum in the electrochemical series; the metal M is selected from alkali metals, alkaline earth metals or combinations thereof. The catalyst can significantly increase the reaction rate, thus allowing the reaction to be operated under very simple experimental conditions such as near atmospheric pressure, with higher reaction yields and higher purity of the products, and without by-products of aluminum metal and unreacted alkali or alkaline earth metals in products, making the handling of the products easier.
Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
Type:
Application
Filed:
August 22, 2023
Publication date:
April 25, 2024
Inventors:
Julie Farand, Michael Graupe, Tezcan Guney, Darryl Kato, Jiayao Li, John O. Link, James B. C. Mack, Dong Min Mun, Roland D. Saito, William J. Watkins, Jennifer R. Zhang
Abstract: The present patent application discloses the compounds according to Formula I shown below, or pharmaceutically acceptable salts thereof, wherein JB, n, R1, R2, R3, R4, R5, m and X as defined herein.
Type:
Application
Filed:
August 31, 2023
Publication date:
April 25, 2024
Inventors:
James Edward Sheppeck, Paul Allan Renhowe, Ara Mermerian, Timothy Claude Barden, Glen Robert Rennie, Rajesh R. Iyengar, Takashi Nakai
Abstract: A platinum complex having a structure of Formula (I) particularly of Formula (A) such as Formula (III) or Formula (IIIa). A pharmaceutical composition includes the platinum complex of the present invention and a pharmaceutically acceptable carrier. A method of treating a target tissue includes administering to a patient in need thereof a platinum complex of the present invention and administering to the target tissue radiation in an amount and of a frequency effective to activate the compound. The platinum complex of the present invention can be used in preparation of a medicament for treating the target tissue by sonodynamic therapy, photodynamic therapy, chemotherapy and/or a combination thereof.
Abstract: Broadly applicable and stereoselective formation of glycosidic linkage remains challenging yet of critical importance in giycoscience. By developing an SN2 glycosylation, this work advances a general solution to this challenge via stereoinversion at the anomeric position of glycosyl ester donors. This SN2 process is enabled by a basic directing-group in the leaving-group, which is activated by a cationic gold catalyst or any other electrophilic reagent. Unlike all the reported directing group approaches, this strategy is applicable to any glycosyl donors—a long sought-after yet unmet goal in carbohydrate chemistry; moreover, the basic directing-group upon glycosylation is lost as part of the leaving-group and hence traceless in the glycoside products, therefore avoiding potential complications in downstream transformations. Highly selective construction of glycosidic bonds including challenging 1,2-cis glycosidic bonds is achieved in excellent yields.
Type:
Application
Filed:
January 28, 2022
Publication date:
April 25, 2024
Applicant:
The Regents of the University of California
Abstract: A D-galactopyranose compound of formula (1) wherein the pyranose ring is beta-D-galactopyranose, and these compounds are high affinity galectin-1 and/or 3 inhibitors for use in treatment of a disorder relating to the binding of a galectin-1 and/or 3 to a ligand in a mammal.
Type:
Application
Filed:
December 21, 2021
Publication date:
April 25, 2024
Applicant:
GALECTO BIOTECH AB
Inventors:
Fredrik ZETTERBERG, Kristoffer PETERSON
Abstract: Embodiments of the present disclosure relate to nucleotide with acetal 3?-OH blocking groups. Also provided herein are methods of using fully functionalized nucleotides containing the 3? acetal blocking group for sequencing applications.
Type:
Application
Filed:
September 28, 2023
Publication date:
April 25, 2024
Inventors:
Antoine FRANCAIS, Elena CRESSINA, Angelica MARIANI, Adam CULLEY, Anno KOETJE, Xiaohai LIU
Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
Type:
Application
Filed:
November 1, 2023
Publication date:
April 25, 2024
Inventors:
Lijing CHEN, Roland Joseph BILLEDEAU, Jim LI
Abstract: Provided is an oligonucleotide primer with an acyclic nucleoside structure for initial capping, which has a molecular structural formula of m7UNGpppA2?omepG, and has higher mRNA in vitro transcription efficiency, higher capping efficiency, lower immunogenicity and higher protein translation efficiency.
Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, and R3 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
Type:
Application
Filed:
June 29, 2023
Publication date:
April 25, 2024
Inventors:
Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison
Abstract: The present invention provides a crystal of a compound represented by formula I as a 3-hydroxy-5-pregnane-20-one derivative and a preparation method therefor. Specifically, the present invention provides novel crystal forms A-C of the compound represented by formula I and a preparation method therefor. The novel crystal forms of the compound represented by formula I of the present invention have excellent thermal stability and mechanical stability, the preparation process thereof is simple, and the novel crystal forms have an excellent industrial implementation potential.
Type:
Application
Filed:
January 27, 2022
Publication date:
April 25, 2024
Inventors:
Fei LIU, Gang WU, Xianchao LI, Xiaobo WANG, Jinwei LIU
Abstract: A method is for purifying a biomolecule (protein, DNA) of interest from a culture of Gram-negative bacteria uses polyoxyethylene isooctylcyclohexyl ether to remove endotoxins. Polyoxyethylene isooctylcyclohexyl ether is used to remove endotoxins and a solution having a pH between 8.0 and 9.0 and a concentration of salts from 2.5M to 3M in chromatography is used for specific leaching of bacterial contaminants.
Type:
Application
Filed:
February 28, 2022
Publication date:
April 25, 2024
Applicant:
XPRESS BIOLOGICS
Inventors:
Marc DAUKANDT, Philippe LEDENT, Christian RODRIQUEZ
Abstract: The present invention relates to protein purification, primarily in the chromatographic field. More closely, the invention relates to affinity chromatography using a split intein system with an improved C-intein tag and N-intein ligand, wherein the target protein may be purified as a tag-less end product with a native N-terminus.
Type:
Application
Filed:
November 20, 2020
Publication date:
April 25, 2024
Inventors:
Christopher James Sevinsky, Peter Lundback, Johan Ohman, Gregory Grossmann, Sean R. Dinn
Abstract: The present invention relates to a method of processing or fractionating a sample comprising proteins, polypeptides and/or peptides, said method comprising (a) changing the physicochemical conditions of said sample; and (b) performing one or both of the following (i) and (ii): (i) adding solid particulate matter to said sample; and (ii) performing said method in a vessel with a rough surface; wherein steps (a) and (b) can be effected concomitantly or in any order; and wherein said processing or fractionating yields one or more first fractions of proteins, polypeptides and/or peptides as a precipitate on said particulate matter and/or said inhomogeneous surface, and a second fraction of proteins, polypeptides and/or peptides remaining in a supernatant.
Type:
Application
Filed:
February 22, 2022
Publication date:
April 25, 2024
Inventors:
Nils A. Kulak, Sebastian H. Johansson, Katrin Hartinger
Abstract: Provided is a preparation method for a modified toxin polypeptide. The preparation method comprises: step 1): expressing a modified toxin polypeptide precursor; step 2): enriching the toxin polypeptide precursor; and step 3): activating the toxin polypeptide precursor to obtain a modified toxin polypeptide.
Abstract: A cell lysis buffer separation apparatus for preparing a polypeptide, and a system and the application thereof. The system comprises a polypeptide enrichment module, wherein the polypeptide enrichment module comprises a cell lysis buffer separation apparatus, and the cell lysis buffer separation apparatus comprises a multi-filtration device and a waste discharge pipeline, the waste discharge pipeline being connected to the multi-filtration device. The system can perform multi-filtration treatment on a lysis buffer. Therefore, the yield of target protein can be increased; and a waste liquid obtained by means of the system contains almost no toxin polypeptide precursor with low toxicity, and has very little toxicity to an operating environment, and same can be directly discharged after simple disinfection treatment, thereby greatly reducing production cost and promoting large-scale industrial production of polypeptide under the conditions of ensuring the safety of the environment and the safety of operators.
Abstract: Peptide compounds and their use in treating diseases and disorders that cause, are caused by, or are characterized by cellular oxidative stress.
Type:
Application
Filed:
June 6, 2023
Publication date:
April 25, 2024
Inventors:
Hampar L. Karageozian, Vicken H. Karageozian, John Y. Park
Abstract: Novel cyclic peptides, cyclic peptide conjugates and compositions containing them for treating neurological diseases in a subject include an Odorranalectin (OL) sequence or modified OL sequence as a scaffold and a biologically active peptide or protein and/or therapeutic agent conjugated thereto. Methods of treatment of neurological diseases are based on intranasal delivery of a cyclic peptide or cyclic peptide conjugate as described herein. Combinatorial libraries that include a plurality of cyclic peptides have also been developed and can be used to screen for a ligand(s) for a receptor of interest.
Abstract: This disclosure features structurally-stabilized and/or cysteine-reactive peptide inhibitors for selective targeting of BFL-1, or dual targeting of BFL-1 and MCL-1. Also disclosed are methods of using such structurally-stabilized and cysteine-reactive peptides in the treatment of BFL-1- and/or MCL-1-expressing or -dependent cancers or diseases of cellular excess (e.g., autoimmune or inflammatory conditions). Also provided are combination therapies comprising such structurally-stabilized and/or cysteine-reactive peptides and inhibitors of the DNA damage response pathway, such as an ATM kinase inhibitor, ATR kinase inhibitor, CHK1/2 inhibitor, or PARP inhibitor; or an inhibitor of MCL-1, or a selective inhibitor of BCL-2, or an inhibitor of BCL-2/BCL-XL, for the treatment of BFL-1-expressing or -dependent cancers (e.g., AML), BFL-1 and MCL-1-expressing or -dependent cancers, or diseases of cellular excess (e.g., autoimmune or inflammatory conditions).
Type:
Application
Filed:
October 24, 2023
Publication date:
April 25, 2024
Inventors:
Loren D. Walensky, Gregory H. Bird, Rachel Guerra, Edward Harvey
Abstract: Disclosed is a combination of peptide linkers for protein covalent self-assembly using a spontaneous isopeptide bond, including a peptide linker 1 and a peptide linker 2. The peptide linker 1 contains a peptide chain having an amino acid sequence as shown in SEQ ID NO: 5, and the peptide linker 2 contains any one or more of peptide chains having amino acid sequences as shown in SEQ ID NOs: 11, 13, 14, and 46. The present disclosure constructs a novel protein self-assembly system based on an isopeptide bond, which effectively solves the problem of low binding efficiency of an existing SpyTag/SpyCatcher system, can significantly improve the reaction efficiency of molecules or components fused to a peptide tag and polypeptide thereof, and has a binding efficiency stronger than that of a SpyTag003/SpyCatcher003 system.
Abstract: The present invention relates to designed ankyrin repeat domains having a reduced isoelectric point (pI) and/or having a reduced number of basic amino acid residues. The invention also provides such repeat domains linked to a drug moiety, for example a radionuclide or a cytotoxic agent. The invention furthermore provides methods for producing such repeat domains, as well as the use of such repeat domains in therapeutic and/or diagnostic methods. In addition, the invention provides recombinant proteins comprising such repeat domains, nucleic acids encoding such repeat domains or recombinant proteins, pharmaceutical compositions comprising such repeat domains, recombinant proteins nucleic acids, recombinant expression vectors and host cells, and the use of such proteins, nucleic acids or pharmaceutical compositions in methods for treating diseases, such as cancer.
Type:
Application
Filed:
July 30, 2023
Publication date:
April 25, 2024
Inventors:
Andreas BOSSHART, Daniel STEINER, Christian REICHEN
Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
Type:
Application
Filed:
April 2, 2023
Publication date:
April 25, 2024
Applicants:
Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1
Inventors:
Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
Abstract: The present invention provides stable pre-fusion respiratory syncytial virus (RSV) FB proteins, nucleic acid molecules and vectors encoding such proteins, and compositions comprising said proteins, nucleic acid molecules and/or vectors, and uses thereof for the prevention and/or treatment of RSV infection.
Type:
Application
Filed:
February 18, 2022
Publication date:
April 25, 2024
Inventors:
Johannes Petrus Maria LANGEDIJK, Tina RITSCHEL, Mark Johannes Gerardus BAKKERS
Abstract: Methods for synthesizing nanowires are provided. Modified PilA peptides are used as peptide building blocks for synthesizing the nanowires. The method places the peptide building blocks in an assembly buffer with a hydrophobe. Addition of a hydrophobe and molecular crowding by evaporation of the assembly buffer triggers the self-assembly of the peptide building blocks into fibers. Multiple elongation cycles of addition of peptide building blocks, mixing and evaporation are conducted to promote elongation of the fibers and synthesis of nanowires. Electronic characterization of the synthesized nanowires is provided.
Abstract: The present invention provides mutated fHbp polypeptides and fusion proteins comprising said mutated fHbp polypeptides that are useful as components of immunogenic compositions for immunizing against Neisseria meningitidis infection.
Abstract: Disclosed herein are nanopore tweezer systems that can be used to screen for allosteric inhibitors of protein kinases. In some embodiments, the protein kinase is a mutant kinase that confers resistance to chemotherapeutic drugs during cancer treatment. Therefore, the disclosed systems and methods can be used to identify drugs for treating drug resistant cancers.
Abstract: The present invention relates to proteins and nucleic acids derived from Staphylococcus aureus as well as therapeutic and diagnostic uses of the proteins and nucleic acids.
Type:
Application
Filed:
October 1, 2023
Publication date:
April 25, 2024
Inventors:
Niels Iversen Møller, Andreas Holm Mattson
Abstract: The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 (I) and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.
Type:
Application
Filed:
August 4, 2021
Publication date:
April 25, 2024
Applicants:
SPEXIS AG, UNIVERSITÄT ZÜRICH
Inventors:
Daniel OBRECHT, Anatol LUTHER, Grégory UPERT, Nicolas DESJONQUERES, Emile BRABET, Peter ZBINDEN, Oliver ZERBE, Kerstin MÖHLE
Abstract: The present invention relates to the use of a sequence chosen among Seq ID No 3, Seq ID No 1, Seq ID No 2, Seq ID No 4, Seq ID No 5, Seq ID No 6, Seq ID No 7, Seq ID No 8, and functional variants thereof, as an odorant binding protein (OBP).
Type:
Application
Filed:
February 23, 2022
Publication date:
April 25, 2024
Applicants:
SPECIALITES PET FOOD, Institut national de recherche pour l’agriculture, l’alimentation et l’environnement, UNIVERSITE DE BOURGOGNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL SUPERIEUR DES SCIENCES AGRONOMIQUES, DE L'ALIMENTATION ET DE L'ENVIRONNEMENT
Abstract: The invention relates to immunogenic peptides derived from Aquaporin 4 (AQP4) for use in the treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD) and to the generation of cytolytic CD4+ T cells or NKT cells against antigen presenting cells that present the wild-type AQP4 epitope sequence.
Abstract: Provided herein are, inter alia, compositions and methods for demethylating and methylating a target DNA sequences in a mammalian cell. The compositions and methods are, inter alia, useful for modulating the expression of a target gene, or to create a gene regulatory network.
Type:
Application
Filed:
August 23, 2023
Publication date:
April 25, 2024
Applicant:
The Jackson Laboratory
Inventors:
Albert Cheng, Aziz Taghbalout, Nathaniel Jillette
Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
Abstract: The present disclosure relates to compositions and methods for reducing expression of MYC gene in a cell. In some embodiments, an expression repressor comprises a targeting moiety that binds a MYC promoter, anchor sequence, or super-enhancer. In some embodiments, the expression repressor comprises an effector moiety that represses transcription or methylates DNA. Systems comprising two expression repressors are also disclosed. The compositions can be used, for example, to treat cancers such as HCC or NSCLC.
Type:
Application
Filed:
December 15, 2021
Publication date:
April 25, 2024
Inventors:
Abigail Elizabeth WITT, Jeremiah Dale FARELLI, Adam Walter SCHEIDEGGER, William Thomas SENAPEDIS, Jr., Jodi Michelle KENNEDY, Houda BELAGHZAL, Defne YARAR, Eugine LEE
Abstract: Provided herein is a fusion protein comprising: (a) an extracellular domain comprising a first binding moiety that is capable of specifically binding to a first cell surface marker: (b) a transmembrane domain: and (c) an intracellular domain comprising: i. a first dimerization domain that specifically binds to a corresponding target dimerization domain in a target protein: and ii. a degradation domain, wherein the degradation domain is a degron or E3 ligase-recruiting domain. Protein circuits. cells and methods that make use of the fusion protein are also provided.
Type:
Application
Filed:
March 13, 2022
Publication date:
April 25, 2024
Inventors:
Andrew H. NG, Matthew KIM, Hana EL-SAMAD